Pharmacokinetics of omeprazole in cirrhotic patients.

Omeprazole (CAS 73590-58-6), an H+, K+ ATPase inhibitor, is a potent suppressor of gastric acid secretion and a very active substance in the treatment of duodenal and gastric ulcers. The kinetic profile of omeprazole is well defined for healthy volunteers and for some high-risk population, but not so far for patients with liver disease. As the substance is mainly metabolized in the liver, changes in liver circulation and/or function might lead to changes in the pharmacokinetics of omeprazole.

[Infective food poisoning. Physiopathology, clinical aspects, therapy].

The nosographic classification of infective food poisoning is still the subject of controversy. At any rate, by and large the pathophysiological mechanisms and their manifestations appear to be clear. After discussing the etiopathogenetic features of the most frequently observed forms, the authors describe ways of transmission, clinical manifestations, diagnostic possibilities and consequent therapeutic management.

Omeprazole vs. ranitidine in the short-term treatment of duodenal ulcer: an Italian multicenter study.

A double-blind, double-dummy, randomized Italian multicenter trial was carried out to compare the efficacy and safety of omeprazole 20 mg in the morning and ranitidine 150 mg b.i.d.